Durvalumab extends survival in small cell lung cancer but raises cost concerns
A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living…
Inflammation and immune suppression fuel aggressive SCLC behavior and spread
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year…
Tip Sheet: What cancer patients need to know about tumor markers, a new cancer genetics atlas — and educational programs for students and teachers
SEATTLE — Sept. 3, 2025 — Below are summaries of recent Fred Hutch Cancer Center research findings, patient…
Tip Sheet: What cancer patients need to know about tumor markers, a new cancer genetics atlas — and educational programs for students and teachers
SEATTLE — Sept. 3, 2025 — Below are summaries of recent Fred Hutch Cancer Center research findings, patient…
MET Inhibitor With Chemoimmunotherapy Overcomes Treatment Resistance in Some Patients With SCLC
Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy when treating patients with small…
Eating more ultra-processed food raises your risk of lung cancer
A 12-year study of over 100,000 adults reveals that your grocery shop may be increasing your risk of…
NKAPL identified as a tumor suppressor and therapeutic target in NSCLC
Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer cases and is often diagnosed at…